Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating of “Buy” from Analysts

Immunic, Inc. (NASDAQ:IMUX) has been assigned an average recommendation of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $7.40.

IMUX has been the subject of a number of research reports. Roth Mkm began coverage on Immunic in a research note on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Thursday, October 16th. HC Wainwright reduced their price target on shares of Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. Finally, Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a report on Wednesday, November 19th.

Immunic Stock Performance

Shares of IMUX stock opened at $0.63 on Friday. The firm has a market cap of $75.18 million, a P/E ratio of -0.75 and a beta of 1.54. The firm’s 50 day moving average price is $0.63 and its 200-day moving average price is $0.78. Immunic has a one year low of $0.51 and a one year high of $1.39.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. As a group, research analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Trading of Immunic

Hedge funds have recently modified their holdings of the stock. Qube Research & Technologies Ltd purchased a new position in Immunic in the third quarter valued at $29,000. Two Sigma Investments LP purchased a new stake in Immunic during the 3rd quarter worth about $52,000. HB Wealth Management LLC acquired a new stake in Immunic in the 3rd quarter valued at about $81,000. Virtu Financial LLC purchased a new position in shares of Immunic in the 3rd quarter valued at about $99,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Immunic in the 3rd quarter valued at about $170,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.